India · Delayed Price · Currency is INR Q-Line Biotech Statistics
Total Valuation
Q-Line Biotech has a market cap or net worth of INR 14.27 billion. The enterprise value is 15.76 billion.
| Market Cap | 14.27B |
| Enterprise Value | 15.76B |
Important Dates
The last earnings date was Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q-Line Biotech has 23.33 million shares outstanding. The number of shares has increased by 6.78% in one year.
| Current Share Class | 23.33M |
| Shares Outstanding | 23.33M |
| Shares Change (YoY) | +6.78% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 71.27% |
| Owned by Institutions (%) | 2.11% |
| Float | 6.47M |
Valuation Ratios
The trailing PE ratio is 17.00.
| PE Ratio | 17.00 |
| Forward PE | n/a |
| PS Ratio | 4.11 |
| PB Ratio | 5.70 |
| P/TBV Ratio | 5.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 85.72 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 27.38 |
| EV / Sales | 4.54 |
| EV / EBITDA | 14.89 |
| EV / EBIT | 16.28 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.92.
| Current Ratio | 1.64 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 2.16 |
| Debt / FCF | n/a |
| Interest Coverage | 5.04 |
Financial Efficiency
Return on equity (ROE) is 25.55% and return on invested capital (ROIC) is 20.80%.
| Return on Equity (ROE) | 25.55% |
| Return on Assets (ROA) | 11.76% |
| Return on Invested Capital (ROIC) | 20.80% |
| Return on Capital Employed (ROCE) | 27.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 9.57M |
| Profits Per Employee | 1.59M |
| Employee Count | 357 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.45 |
Taxes
In the past 12 months, Q-Line Biotech has paid 168.28 million in taxes.
| Income Tax | 168.28M |
| Effective Tax Rate | 23.20% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 612.54 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.42 |
| Average Volume (20 Days) | 75,620 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Q-Line Biotech had revenue of INR 3.42 billion and earned 567.13 million in profits. Earnings per share was 35.41.
| Revenue | 3.42B |
| Gross Profit | 2.07B |
| Operating Income | 954.06M |
| Pretax Income | 725.50M |
| Net Income | 567.13M |
| EBITDA | 1.04B |
| EBIT | 954.06M |
| Earnings Per Share (EPS) | 35.41 |
Balance Sheet
The company has 764.37 million in cash and 2.25 billion in debt, with a net cash position of -1.49 billion or -63.89 per share.
| Cash & Cash Equivalents | 764.37M |
| Total Debt | 2.25B |
| Net Cash | -1.49B |
| Net Cash Per Share | -63.89 |
| Equity (Book Value) | 2.46B |
| Book Value Per Share | 151.27 |
| Working Capital | 1.34B |
Cash Flow
In the last 12 months, operating cash flow was 163.76 million and capital expenditures -359.14 million, giving a free cash flow of -195.38 million.
| Operating Cash Flow | 163.76M |
| Capital Expenditures | -359.14M |
| Depreciation & Amortization | 88.58M |
| Net Borrowing | 605.33M |
| Free Cash Flow | -195.38M |
| FCF Per Share | -8.38 |
Margins
Gross margin is 60.59%, with operating and profit margins of 27.92% and 16.31%.
| Gross Margin | 60.59% |
| Operating Margin | 27.92% |
| Pretax Margin | 21.23% |
| Profit Margin | 16.31% |
| EBITDA Margin | 30.51% |
| EBIT Margin | 27.92% |
| FCF Margin | n/a |
Dividends & Yields
Q-Line Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.78% |
| Shareholder Yield | -6.78% |
| Earnings Yield | 4.04% |
| FCF Yield | -1.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q-Line Biotech has an Altman Z-Score of 2.04 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.04 |
| Piotroski F-Score | 4 |